ArticleJAMA network open2025
Alcohol-Associated Liver Disease Mortality.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- The global burden of metabolic and alcohol-associated liver disease (MetALD).Hepatology communications · 2026Review
- Temporal trends and demographic disparities in mortality with co-mention of chronic liver disease and pneumonia in the United States, 1999-2024.BMC gastroenterology · 2026Article
- Time-Varying Impact of Steatosis and Alcohol on Mortality: A Marginal Structural Model of the Canadian Longitudinal Study on Aging.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Cardiovascular and hepatic outcomes: prognostic differences across MASLD-MetALD-ALD continuum.Clinical and molecular hepatology · 2026Review
- Global epidemiological patterns and disease burden of metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease.Clinical and molecular hepatology · 2026Review
- Platelet-derived S100A9 contributes to endotheliopathy in alcohol-associated hepatitis.JCI insight · 2026Article
- Disparities in Outcomes of Alcohol-Associated Hepatitis in the United States: Insights from the National Inpatient Sample, 2016-2022.Journal of racial and ethnic health disparities · 2026Article
- Temporal Trends and Demographic Disparities in Respiratory Failure Mortality Among Adults with Chronic Liver Disease: A National Mortality Database Analysis, 1999 to 2024.Diseases (Basel, Switzerland) · 2026Article
- Correspondence to letter to the editor on "Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States".Clinical and molecular hepatology · 2026Article
- Day-Level Mediators of Change in Brief Motivational Intervention for Alcohol Use and Liver Health.Research square · 2026Article
- Ethanol-Tolerant Lactobacillus rhamnosus L7 Ameliorates Alcohol-Induced Liver Injury in Mice by Inhibiting the TLR4/MyD88/NF-κB Inflammatory Signaling Pathway and Restoring Gut Microbiota Homeostasis.Probiotics and antimicrobial proteins · 2026Article
- Heavy Drinking, Alcohol Use Disorder, and Obesity.JAMA internal medicine · 2026Article
- Stable Nationwide Sepsis-Related Mortality Does Not Extend to Individuals with Alcohol-Associated Liver Disease.Digestive diseases and sciences · 2026Article
- Trends in atrial fibrillation and non-alcoholic fatty liver disease-related mortality in the United States from 1999 to 2020: a CDC WONDER analysis.Annals of medicine and surgery (2012) · 2026Review
- Gut-liver axis molecular mechanisms in alcohol-associated liver disease.Alcohol (Fayetteville, N.Y.) · 2026Review
- Closing the Implementation Gap: New Models of Care to End Chronic Liver Disease.The Lancet regional health. Europe · 2026Article
- Prevalence, Clinical Profiles, Disease Severity, and Patient Outcomes of Alcoholic Liver Disease in a Tertiary Care Hospital of Nepal.Health science reports · 2026Article
- The global epidemiology of alcohol-associated liver disease.Hepatology communications · 2026Review
- Demographic and Geographic Disparities in Atrial Fibrillation and Cirrhosis Mortality in the United States: A Twenty-Five-Year Analysis From 1999 to 2023.Cardiology research · 2026Article
- Addressing Chronic Steatotic Liver Disease through Community Partnerships, Integrated Behavioral Interventions, and Point-of-Care Diagnostics.Rhode Island medical journal (2013) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Alcohol-associated liver disease (ALD) is a major public health concern, accounting for one-quarter of cirrhosis-related deaths and becoming the leading indication for liver transplantation in the US, with concerning increases in mortality during and following the COVID-19 pandemic onset. Objective: To evaluate comprehensive national trends in ALD mortality in the US from 1999 to 2022, with a particular focus on disparities related to sex, race, ethnicity, and age. Design, Setting, and Participants: This retrospective cross-sectional analysis used the Centers for Disease Control and Prevention Wide Ranging Online Data for Epidemiologic Research mortality database from 1999 to 2022, examining death certificates across all 50 states and the District of Columbia. The study included individuals aged 25 years and older. Data analysis was performed from September to November 2024. Exposure: ALD mortality was identified using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes (K70.xx) for both alcohol-associated hepatitis (K70.1x) and alcohol-associated cirrhosis (K70.3x). Main Outcomes and Measures: Primary outcomes included age-adjusted annual mortality rates per 100 000 population, stratified by sex, age groups (25-44, 45-64, 65-84, and ≥85 years), race and ethnicity, and geographic regions. Joinpoint regression analysis was used to calculate average annual percentage changes (AAPCs) and to identify significant trend changes. Results: In this study, a total of 436 814 ALD deaths were recorded (308 923 men [70.7%]), with ALD mortality increasing from 6.71 to 12.53 deaths per 100 000 between 1999 and 2022 and significant acceleration during 2018 to 2022 (annual percentage change [APC], 8.94%; 95% CI, 6.27% to 14.51%; P = .001). Women showed more rapid increases than men (AAPC, 4.29% [95% CI, 3.09% to 5.51%] vs 2.50% [95% CI, 1.51% to 3.51%]), whereas young adults (aged 25-44 years) demonstrated concerning trends (AAPC, 4.23%; 95% CI, 3.47% to 4.83%; P = .001). American Indian and Alaska Native populations experienced the highest mortality rates, increasing from 25.21 to 46.75 deaths per 100 000 (AAPC, 4.93%; 95% CI, 3.45% to 5.96%; P = .001). Alcohol-associated hepatitis mortality increased from 0.47 to 0.76 deaths per 100 000 (AAPC, 2.08%; 95% CI, 1.27% to 3.05%; P = .001), with women showing steeper increases than men (AAPC, 3.94% [95% CI, 2.58% to 5.46%] vs 1.56% [95% CI, 0.73% to 2.42%]). Alcohol-associated cirrhosis mortality increased from 4.09 to 9.52 deaths per 100 000 (AAPC, 4.00%; 95% CI, 3.63% to 4.40%; P = .001), with particularly concerning trends among women (APC from 2011 to 2022, 8.32%; 95% CI, 7.40% to 9.82%; P = .01) and adults aged 25 to 44 years (APC from 2018 to 2022, 19.51%; 95% CI, 15.00% to 28.53%; P = .001). Conclusions and Relevance: In this cross-sectional study using data from the Centers for Disease Control and Prevention Wide Ranging Online Data for Epidemiologic Research database, ALD mortality increased significantly across demographic groups, with particularly concerning trends among women, younger adults, and American Indian and Alaska Native populations. These findings highlight the urgent need for targeted public health interventions and enhanced surveillance, especially given the sustained impact of COVID-19 pandemic-related changes in alcohol consumption patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.